912758-00-0

Basic information

• Product Name: ATB-337
• Synonyms: ATB-337;ACS 15;S-Diclofenac;BRDUXOHVEZVAHI-UHFFFAOYSA-N
• CAS NO: 912758-00-0
• Molecular Formula: C23H15Cl2NO2S3
• Molecular Weight: 504.4717
• Mol File: 912758-00-0.mol

Chemical Properties

• Appearance: /
• Solubility: ≤10mg/ml in DMSO;10mg/ml in dimethyl formamide
• CAS DataBase Reference: ATB-337(CAS DataBase Reference)
• NIST Chemistry Reference: ATB-337(912758-00-0)
• EPA Substance Registry System: ATB-337(912758-00-0)

Safety Data

• Hazardous Substances Data: 912758-00-0(Hazardous Substances Data)

Usage

Biological Activity

atb-337 is a hybrid molecule of an h2s donor and the nsaid diclofenac [1].hydrogen sulfide (h2s) is a newly recognized signaling molecule with potent cytoprotective actions. hydrogen sulfide has been involved in mediating many physiological processes, such as the maintenance of gastrointestinal mucosal defense and repair. hydrogen sulfide also exerts many anti-inflammatory effects, including inhibition of leukocyte adherence to the vascular endothelium and leukocyte migration to sites of inflammation [2].oral administration of atb-337 did not produce any hemorrhagic erosions. oral administration of an equimolar dose of atb-337 produced > 90% less small intestinal damage and showed no significant effect on the hematocrit. in rats, administration of atb-337 (50 μmol/kg) showed no significant effect on leukocyte adherence. oral administration of atb-337 significantly increased plasma levels of h2s by > 40%. in a rat air pouch model, atb-337 (1 μmol/kg) suppressed cox-2 activity. in the rat, atb-337 inhibited thromboxane synthesis. atb-337 suppressed arachidonic acid–induced human platelet aggregation. pretreatment with atb-337 (10 μmol/kg) reduced paw swelling. atb-337 generated ～12nmol/min of h2s when it was incubated in buffer.

references

[1] wallace j l, caliendo g, santagada v, et al. gastrointestinal safety and anti-inflammatory effects of a hydrogen sulfide–releasing diclofenac derivative in the rat[j]. gastroenterology, 2007, 132(1): 261-271.[2] wallace j l. physiological and pathophysiological roles of hydrogen sulfide in the gastrointestinal tract[j]. antioxidants & redox signaling, 2010, 12(9): 1125-1133.

Upstream product

• 18274-81-2 desmethyl anethole trithione 
• 15307-86-5 [2-(2,6-dichloroanilino)phenyl]acetic acid 

Relevant articles and documents

Modulation of angiogenesis by dithiolethione-modified NSAIDs and valproic acid

Background and purpose: Angiogenesis involves multiple signaling pathways that must be considered when developing agents to modulate pathological angiogenesis. Because both cyclooxygenase inhibitors and dithioles have demonstrated anti-angiogenic properti

3H-1,2-DITHIOCYCLOPENTENE-3-THIOKETONE COMPOUNDS AND APPLICATION THEREOF

The present invention relates to the field of medicaments, and in particular relates to 3H-1,2-dithiocyclopentene-3-thione compounds and application thereof. 3H-1,2-dithiocyclopentene-3-thione compounds disclosed by the invention have new structures shown in formula I or formula II. Proved by experiments, 3H-1,2-dithiocyclopentene-3-thione compounds can directly protect neurons in a cellular model, and can significantly restrain excessive inflammatory responses of brain inflammatory cells; and by using 3H-1,2-dithiocyclopentene-3-thione, focal ischemic cerebral infarct volumes of mice can be remarkably reduced in an animal model. Therefore, the invention provides the application of 3H-1,2-dithiocyclopentene-3-thione compounds and pharmaceutically acceptable salts thereof in the preparation of medicaments for preventing or treating cerebral apoplexy diseases.

HYDROGEN SULFIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS

The present invention relates to derivatives of non-steroidal anti-inflammatory drugs (NSAIDs) having improved anti-inflammatory properties useful in the treatment of inflammation, pain and fever. More particularly, NSAIDs are derivatized with a hydrogen

NEW ANTI-INFLAMMATORY COMPOUNDS

The present invention relates to novel non steroidal anti-inflammatory compounds (NSAIDs) that release hydrogen sulfide (H2S). The present invention also provides methods for treating, preventing and/or reducing inflammation-associated diseases by releasing H2S in the cardiovascular, connective tissue, pulmonary, gastrointestinal, respiratory, urogenital, nervous, or cutaneous systems as well as infective diseases employing said compounds.